New eye injection trial targets cancer spread from other organs

NCT ID NCT06643884

Recruiting now Disease control Sponsor: Aura Biosciences Source: ClinicalTrials.gov ↗

Summary

This study is testing a new drug called belzupacap sarotalocan for people whose cancer has spread from another part of the body to the eye. The main goal is to see if the treatment is safe and tolerable when injected near the eye. Researchers will also check if the treatment helps shrink the eye tumors.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Bascom Palmer Eye Institute
RECRUITING

Miami, Florida, 33136, United States
Byers Eye Institute at Stanford University
RECRUITING

Palo Alto, California, 94303, United States
Cleveland Clinic, Cole Eye Institute
NOT_YET_RECRUITING

Cleveland, Ohio, 44195, United States
Kellogg Eye Center
RECRUITING

Ann Arbor, Michigan, 48105, United States
Massachusetts Eye and Ear
RECRUITING

Boston, Massachusetts, 02114, United States
Mayo Clinic
NOT_YET_RECRUITING

Rochester, Minnesota, 55905, United States
Retina Consultants of Texas
RECRUITING

Bellaire, Texas, 77401, United States
Shields and Shields, PC
NOT_YET_RECRUITING

Philadelphia, Pennsylvania, 19107, United States
Tennessee Retina, PC
RECRUITING

Nashville, Tennessee, 37203, United States
University of Washington
RECRUITING

Seattle, Washington, 98104, United States

Conditions

Explore the condition pages connected to this study.

EYE CANCER PRIMARY CANCER